Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations.

We read with interest the paper "HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk" by Dr. Morris et al. published in an upcoming issue of Hepatology.1 It is an elegant study looking at the feasibility of using a new set of biomarkers, the HepatoScore-14, to stratify the prognosis of patients with hepatocellular carcinoma (HCC). However, some methodological shortcomings and data interpretation may deserve the authors' attention.